Visi-Pro balloon-Expandable peripheral stent system
Medtronic Vascular, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-16 for P030045/S011, a supplement to the Visi-Pro balloon-Expandable peripheral stent system held by Medtronic Vascular, Inc. The supplement type is listed as a 30-Day Notice with the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the device is categorized as an iliac stent under product code NIO in the Cardiovascular specialty.
The recorded statement covers a sterilization monitoring change: reduced incubation time for the biological indicator used in external process challenge devices. This is a manufacturing process notice, not a new approval of the stent system itself, and the source does not describe the prior or revised incubation interval, the indicator or device maker, or any validation data. No documents are attached, so the sterilization rationale and any effect on finished-device labeling remain unknown from this record.
FDA approval order statement
approval for a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030045/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIO
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, ILIAC.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030045. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030045 · Original PMA
INTRASTENT DOUBLESTRUT STENT
P030045/S011 received
Application receipt date recorded by FDA.
P030045/S011 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P030045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INTRASTENT DOUBLESTRUT STENTP030045 | Medtronic Vascular, Inc. | PMA approval | Jun 8, 2004 | FDA |
Explore the linked device profile
Other records with product code NIO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cook Ireland, Ltd. | PMA supplement | Nov 6, 2026 | FDA | |
S.M.A.R.T. CONTROL Nitinol Stent SystemP020036/S061 | Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Dec 17, 2015 | FDA | |
ZILVER VASCULAR STENTP050017 | Cook Ireland, Ltd. | PMA approval | Jun 26, 2006 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P030045/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




